These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 8625139

  • 21. Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.
    Gridelli C, Curcio C, Iaffaioli RV, Brancaccio L, D'Aprile M, Gebbia V, Rossi A, Tortoriello A, Veltri E, Maione P, Barbarisi A, Gallo C, Guida C, Perrone F.
    Anticancer Res; 2001; 21(6A):4179-83. PubMed ID: 11911315
    [Abstract] [Full Text] [Related]

  • 22. A randomized phase II study of radiation therapy, pemetrexed, and carboplatin with or without cetuximab in stage III non-small-cell lung cancer.
    Bogart JA, Govindan R.
    Clin Lung Cancer; 2006 Jan; 7(4):285-7. PubMed ID: 16512986
    [No Abstract] [Full Text] [Related]

  • 23. Multimodality management of regionally advanced non-small-cell lung cancer.
    Belani CP.
    Semin Oncol; 1993 Aug; 20(4):302-14. PubMed ID: 8393590
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Evaluation of cisplatin, carboplatin, and etoposide in metastatic nonsmall cell lung carcinoma. A phase II study of the Southwest Oncology Group.
    Figlin RA, Crowley JJ, Jacobs EL, Muirhead M, Goodwin JW, Rinehart JJ, Livingston RB.
    Cancer; 1996 Sep 01; 78(5):998-1003. PubMed ID: 8780537
    [Abstract] [Full Text] [Related]

  • 30. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
    Chang AY, Kim K, Boucher H, Bonomi P, Stewart JA, Karp DD, Blum RH.
    Cancer; 1998 Jan 15; 82(2):292-300. PubMed ID: 9445185
    [Abstract] [Full Text] [Related]

  • 31. Cisplatin and carboplatin in combination with etoposide as a treatment for non-small cell lung cancer: the experience of the EORTC Lung Cancer Working Party.
    Klastersky J.
    Cancer Treat Rev; 1988 Jun 15; 15 Suppl B():33-40. PubMed ID: 2841022
    [No Abstract] [Full Text] [Related]

  • 32. Treatment of unresectable nonsmall-cell lung cancer (NSCLC).
    Papacharalambous A, Rigatos G, Alexopoulos A, Stavrakakis J, Scartsilas C, Stavrinidis E.
    J Chemother; 1989 Jul 15; 1(4 Suppl):1214-5. PubMed ID: 16312839
    [No Abstract] [Full Text] [Related]

  • 33. Chemotherapy of non small cell lung cancer. A prospectively randomized study of cisplatin-etoposide versus cisplatin-mitomycin-vinblastine.
    Polyzos A, Tsavaris N, Veslemes M, Dardoufas K, Dosios T, Kosmas C.
    J Chemother; 1997 Apr 15; 9(2):102-5. PubMed ID: 9176747
    [Abstract] [Full Text] [Related]

  • 34. Correspondence re L. J. Wirth et al., Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a phase I study. Clin Cancer Res 2003;9:1698-704.
    Cesario A, Margaritora S, Galetta D, Porziella V, Granone P, D'Angelillo RM, Trodella L, Cardaci V, Sterzi S, Russo P.
    Clin Cancer Res; 2004 Apr 15; 10(8):2902-3; author reply 2904. PubMed ID: 15102699
    [No Abstract] [Full Text] [Related]

  • 35. The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer.
    Bunn PA.
    Semin Oncol; 1996 Dec 15; 23(6 Suppl 16):18-25. PubMed ID: 9007116
    [Abstract] [Full Text] [Related]

  • 36. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2002 Dec 15; 20(24):4665-72. PubMed ID: 12488411
    [Abstract] [Full Text] [Related]

  • 37. Cis/carboplatin + vinorelbine +/- radiotherapy in stage III and IV non small cell lung carcinoma.
    Tomirotti M, Galassi B, Dambrosio M, Fossati V, Gramegna G, Colombo F, Rovej R, Scanni A.
    J Chemother; 1997 Feb 15; 9(1):62-5. PubMed ID: 9106020
    [Abstract] [Full Text] [Related]

  • 38. Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions.
    Bunn PA.
    Semin Oncol; 1997 Aug 15; 24(4 Suppl 12):S12-153-S12-162. PubMed ID: 9331142
    [Abstract] [Full Text] [Related]

  • 39. Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.
    Jiang L, Yang KH, Guan QL, Mi DH, Wang J.
    Intern Med J; 2012 Dec 15; 42(12):1297-309. PubMed ID: 22530708
    [Abstract] [Full Text] [Related]

  • 40. Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: a randomized phase III study. Hellenic Cooperative Oncology Group for Lung Cancer Trials.
    Kosmidis PA, Samantas E, Fountzilas G, Pavlidis N, Apostolopoulou F, Skarlos D.
    Semin Oncol; 1994 Jun 15; 21(3 Suppl 6):23-30. PubMed ID: 8052870
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.